Ambys Medicines Announces Presentation on Novel Liver Cell Therapy Platform for Severe Liver Diseases, and Opening of its cGMP Cell Therapy Manufacturing Facility

Magenta Therapeutics Announces IND Clearance For MGTA-117 Targeted Conditioning Clinical Trial

Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors

Casma Therapeutics Announces Addition of Sharon Tooze, Ph.D. to Scientific Advisory Board

Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer

Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss

MOMA Therapeutics Appoints Semi Trotto as Chief People and Experience Officer

Pliant Therapeutics Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis

insitro Appoints Tom Stocky as Vice President of Product

Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Sesen Bio Receives Complete Response Letter from FDA for Vicineum™ (oportuzumab monatox-qqrs)

Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stockf

Sesen Bio Strengthens Executive Leadership Team as the Company Approaches the Potential Approval and Commercial Launch of Vicineum™

Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress

Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

Decibel Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Updatede

Tango Therapeutics Debuts As Publicly Traded Precision Oncology Company Focused On The Next Generation Of Targeted Cancer Therapies

Goldfinch Bio Announces Initiation of Open-Label Extension Study for Patients with Focal Segmental Glomerular Sclerosis (FSGS) Enrolled in Phase 2 Clinical Trial of GFB-887

Rheos Medicines Appoints Nirupama Subramanian as Chief Operating Officer

Sesen Bio Reports Second Quarter 2021 Financial Results and Significant Global Progress for Vicineum™

Voyager Therapeutics Transforms Pipeline And Increases Investment In Next-Generation TRACER™ AAV Capsid And Vectorized Antibody Platform Technologies

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Jounce Therapeutics Reports Second Quarter 2021 Financial Results

Magenta Therapeutics Reports Second Quarter Financial Results And Recent Program Highlights

Sesen Bio Announces Partnership with Eczacibasi Pharmaceuticals Marketing (EIP) for the Commercialization of Vicineum™ in Turkey

Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum™

Faze Medicines Appoints New Senior Vice President, Head of People & Culture

Sesen Bio Announces New Appointments to its Board of Directors

Magenta Therapeutics Announces Update On U.S. FDA Investigational New Drug Application For MGTA-117 In Patients With Acute Myeloid Leukemia And Myelodysplastic Syndrome

Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum™ in China

Rheos Medicines Appoints Industry Leader, John Davis, Jr., M.D., M.P.H., M.S., to Board of Directors

Jounce Therapeutics to Participate in William Blair’s Biotech Focus Conference

Magenta Therapeutics Appoints Caren Deardorf As Chief Commercial Officer

Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells to Treat Serious Autoimmune and Inflammatory Diseases

Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody

Magenta Therapeutics Appoints Thomas Beetham As Chief Legal Officer

Nurix Therapeutics Announces Upcoming Presentation Of NX-5948 Preclinical Data At The EULAR 2021 Virtual Congress

Voyager Therapeutics Announces Strategic Shift And Leadership Transitions

Flare Therapeutics Launches with $82 Million Series A Financing to Advance Precision Oncology Pipeline based on Novel Drug Discovery Approach for Transcription Factors

Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024, a Novel Precision Medicine Product Candidate for Patients with Severe Insulin Resistant Diabetic Nephropathy (DN)

Magenta Therapeutics Announces $86.4 Million Common Stock Investment From Multiple Investors

Voyager Therapeutics Presents New Preclinical Data Showing Reduction Of Pathological Tau With Vectorized Anti-Tau Antibody

Magenta Therapeutics Announces Positive Preliminary Results From Phase 2 Clinical Trial Of MGTA-145 In Multiple Myeloma And Provides An Update On Its Anticipated Clinical Study With MGTA-117

Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across The Blood Brain Barrier, Widespread CNS Transduction In Non-Human Primates

Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update